相关实验视频

Updated: May 6, 2026

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

瘤治疗场改变了质母细胞瘤患者的局部凝血动态

Claudia Maletzki¹, Thomas Freitag², Adrian Hempelmann²

¹Department of Medicine, Clinic III - Hematology, Oncology, Palliative Medicine, Rostock University Medical Center, University of Rostock, 18057 Rostock, Germany.

Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics

|August 30, 2025

概括

在质母细胞瘤患者中,瘤治疗场 (TTFields) 通过改变外部凝血路径并降低凝血硬度来延长血液凝结. 这种TTFields机制也可能调节瘤微环境中的免疫反应.

科学领域:

癌症学
生物物理
血液学

背景情况:

质母细胞瘤 (GBM) 是一种与高凝血和血栓形成相关的侵袭性脑瘤.
瘤治疗场 (TTFields) 是一种非侵入性疗法,可改善放射化疗治疗的GBM患者的存活率.
在接受TTFields治疗的患者中,明显的GBM复发模式表明与瘤相关的凝血相互作用,但机制尚不清楚.

研究的目的:

研究TTFields对GBM患者和健康捐赠者的凝血概况的影响.
阐明TTFields引起的血液凝固和瘤微环境变化的分子机制.

主要方法:

来自TTFields治疗患者和健康捐赠者的血液,瘤细胞和血衍生的细胞外囊的分子,血液静止学和表型分析.
基于RNA的微阵列分析GBM细胞.
GBM细胞和周围血液的异构共培养模型.

主要成果:

通过改变组织因子 (TF) 表达和破坏外部通路,对TTFields的短期暴露显著延长了血液凝结.
TTFields通过降低因子II/ FXIII活性和血小板数量来降低血栓刚性,而不会影响纤维素.
在共同培养模型中,TTFields调节了凝血和免疫反应,可能通过重新平衡促凝和抗凝因,改变炎症途径.

结论:

在GBM瘤微环境中,TTFields影响血液凝固和免疫调节.
这些发现为优化临床决策和减轻GBM患者的血栓栓塞并发症提供了策略.

关键词:

细胞死亡凝块的刚性血液静止血凝过度组织因子

更多相关视频

Determining the Optimal Inhibitory Frequency for Cancerous Cells Using Tumor Treating Fields TTFields

Determining the Optimal Inhibitory Frequency for Cancerous Cells Using Tumor Treating Fields TTFields

Published on: May 4, 2017

The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma

The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma

Published on: April 16, 2019

相关概念视频

Adaptive Mechanisms in Cancer Cells

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...

The Tumor Microenvironment

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...

Cancer Stem Cells and Tumor Maintenance

Cancer Stem Cells and Tumor Maintenance

Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...

Stem Cell Therapy for Tissue Regeneration

Stem Cell Therapy for Tissue Regeneration

Stem cell therapy is a method used in regenerative medicine to repair and restore function to damaged tissues and organs. Stem cells have the potential to proliferate and differentiate into various tissue types, making them ideal candidates for tissue regeneration. For example, hematopoietic stem cell transplants are commonly used in blood cancer treatment to replenish damaged bone marrow and restore healthy blood cells.
Types of Stem Cells used in Stem Cell Therapy
The two main cell...